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ODS: Data from recently published outcome studies was
incorporated into TreeAge software to construct the one-
year decision analysis model. The primary cost drivers
thought to influence cost-effectiveness were complicated
GI bleeds, hospitalizations, and symptomatic ulcers, as
well as differences in renal toxicity, dyspepsia, anemia,
hypertension and edema. Sensitivity analysis was per-
formed on all major indices based on variations in results
found in reviewed studies. RESULTS: Overall rates of
adverse events were similar for all agents (75% NSAIDs,
72% celecoxib, 78% rofecoxib), however celecoxib was
associated with less events relating to primary cost driv-
ers. These differences are attributed mainly to variances
among adverse event probabilities for hypertension and
edema (NSAIDs 4.7%, 4.4%, celecoxib 1.6%, 2.9%, rofe-
coxib 6.4%, 6.3%, respectively). Cost of drug treatment
per year for NSAIDs, celecoxib, and rofecoxib are $36.00,
$466.00, and $482.00, respectively, based on Federal
Supply Schedule (FSS) pricing. CONCLUSIONS: Based
on preliminary data, therapy with COX-2 inhibitors does
not appear to be cost-effective to prescribe for all os-
teoarthritic patients within the VA Health care System.
Results may be extrapolated to other health care settings
assuming medical costs are similar.
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OBJECTIVES: To evaluate the changes in patient utility
with treatment of active rheumatoid arthritis (RA) with
leflunomide (LEF), placebo (PBO) or methotrexate
(MTX). METHODS: A 52 week multicenter double-
blind controlled trial comparing treatment with lefluno-
mide, methotrexate or placebo in patients with active
rheumatoid arthritis was used to derive patient utilities.
Short Form 36 (SF-36) data were used to generate utility
scores using the algorithm developed by Brazier et al
(1999). These utilities would reflect general population
values and would not be specific to an RA population.
Inclusion in the utility analysis required consistent SF-36
responses, a baseline and at least one other completed as-
sessment, and valid responses to derive the SF-6D utili-
ties. The area under the curve was calculated for com-
pleters and the intent-to-treat population in order to
estimate incremental quality adjusted life years (QALYs)
for the treatments. RESULTS: The clinical study popula-
tion consisted of 182 LEF, 180 MTX and 118 PBO pa-
tients. The population used for the utility analysis con-
sisted of 165 LEF, 164 MTX and 114 (PBO). Baseline
utility values were comparable between groups, ranging
from 0.622 to 0.637. Incremental QALYs gained for
completers was statistically significantly superior for LEF
over PBO (p  0.0317) and MTX (p  0.0130). Treat-
ment with LEF resulted in an incremental gain of 0.084
QALYs, starting from a baseline of 0.622. Similar results
were seen with the intent-to-treat population. CONCLU-
SIONS: Treatment of RA with LEF statistically improves
patient health state utility values and QALY gain over
MTX and PBO.
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OBJECTIVES: To evaluate the stability and discrimina-
tive ability of direct and indirect measures of utility in a
population of rheumatoid arthritis patients. METHODS:
Clinical trial data was used to compare the stability of di-
rect measures of utility (SG and VAS) to that from an in-
direct approach to utility development (SF-6D). SF-36
data were transformed to the SF-6D utility using the al-
gorithm developed by Brazier et al.(1999) based on val-
ues of the general UK population. These data were com-
pared to SG and VAS data collected in the same trial.
Ability to discriminate across functional classes and vari-
ance around point estimates was examined. RESULTS:
The SF-6D generated utilities that were consistently
lower than the directly elicited SG and were closer to the
VAS valuations. The standard deviations, however, were
consistently smaller.
CONCLUSIONS: The indirect measure of utility (SF-6D)
was more stable in terms of variance of parameter esti-
mates and was able to discriminate across functional
classes. The reduced variance around these estimates en-
hances statistical testing and accurately reflects changes
experienced by the patient.
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BACKGROUND: Regence BlueShield, a 1.2 million-
member Washington health plan currently requires prior
Baseline Week 24 Week 52
SG 0.7759 (0.2399) 0.8684 (0.1850) 0.8794 (0.1858)
VAS 0.5902 (0.1942) 0.7425 (0.1623) 0.7701 (0.1629)
SF-6D 0.6287 (0.1290) 0.7323 (0.1109) 0.7443 (0.1089)
